Dendritic cell-based vaccine research against cancer

Expert Review of Clinical Immunology

Volumn 11, Issue 2, 2015, Pages 213-232

  Mody, Nishi ^a   Dubey, Surbhi ^a   Sharma, Rajeev ^a   Agrawal, Udita ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

cancer; DC subsets; dendritic cell; receptors; targeting; vaccination

Indexed keywords

CD209 ANTIGEN; DENDRITIC CELL VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; MANNOSE RECEPTOR; TUMOR ANTIGEN; CANCER VACCINE;

ACTIVE IMMUNIZATION; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD34 SELECTION; CELL FUNCTION; CELL SUBPOPULATION; CLINICAL STUDY; DENDRITIC CELL; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; EX VIVO STUDY; EXPERIMENTAL MODEL; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MONOCYTE; NEOPLASM; REVIEW; STEM CELL; TH1 CELL; TH2 CELL; ANIMAL; IMMUNOLOGY; MEDICAL RESEARCH; NEOPLASMS;

ANIMALS; BIOMEDICAL RESEARCH; CANCER VACCINES; DENDRITIC CELLS; HUMANS; NEOPLASMS;

EID: 84921340389     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.987663     Document Type: Review

References (170)

1. Nabel GJ. Designing tomorrows vaccines. N Engl J Med 2013; 368: 551-60
2. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011; 12: 509-17
3. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12: 557-69
4. Lizee G, Overwijk WW, Radvanyi L, et al. Harnessing the power of the immune system to target cancer. Annu Rev Med 2013; 64: 71-90
5. Palucka K, Banchereau J. Dendritic-Cell-Based therapeutic cancer vaccines. Immunity 2013; 39: 38-48
6. Kumar PV, Prasanthi S, Lakshmi VRS, Santosh MVS. Cancer vaccines: a promising role in cancer therapy. Acad J Cancer Res 2010; 3(2): 16-21
7. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193(2): 233-8
8. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12(4): 265-77
9. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004; 53: 275-306
10. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999; 223: 1-15
11. Bender A, Sapp M, Schuler G, et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996; 196: 121-35
12. Bonab SF, Salehi TZ, Khansari N, et al. An optimized method for ex vivo generation of dendritic cells. J Vet. Res 2014; 69(1): 17-23
13. Chen Hao W, Liao Cheng H, Ying C, et al. Ex vivo expansion of dendritic-cell-Activated antigen-specific CD4 + T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy. Clinical Immunol 2006; 119: 21-31
14. Chinnasamy N, Treisman JS, Oaks MK, et al. Ex vivo generation of genetically modified dendritic cells for immunotherapy: implications of lymphocyte contamination. Gene Ther 2005; 12: 259-71
15. Seliger B, Kellner R. Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets. Proteomics 2002; 2: 1641-51
16. Satthaporn S, Eremin O. Dendritic cells (I): biological functions. J R Coll Surg Edinb 2001; 46: 9-20
17. Uenoa H, Klechevsky E, Schmitt N, et al. Targeting human dendritic cell subsets for improved vaccines. Semin Immunol 2011; 23: 21-7
18. Di Pucchio T, Chatterjee B, Smed-Sorensen A, et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 2008; 9(5): 551-7
19. Cao W, Rosen DB, Ito T, et al. Plasmacytoid dendritic cell-specific receptor ILT7-Fc{varepsilon}RI{gamma} inhibits Toll-like receptor-induced interferon production. J Exp Med 2006; 203(1): 399-405
20. Matsui T, Connolly JE, Michnevitz M, et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009; 182(11): 6815-23
21. Tel J, Aarntzen EH, Baba T, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013; 73: 1063-75
22. Jego G, Palucka AK, Blanck JP, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19(2): 225-34
23. Shaw J, Wang YH, Ito T, et al. Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. Blood 2010; 115(15): 3051-7
24. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194(6): 863-9
25. Meixlsperger S, Leung CS, Ramer PC, et al. CD141+ dendritic cells produce prominent amounts of IFN-A after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 2013; 121: 5034-44
26. Huysamen C, Willment JA, Dennehy KM, et al. CLEC9A is a novel activation C-Type lectin-like receptor expressed on BDCA3+dendritic cells and a subset of monocytes. J Biol Chem 2008; 283(24): 693-701
27. Segura E, Valladeau-Guilemond J, Donnadieu MH, et al. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med 2012; 209: 653-60
28. Yu CI, Becker C, Wang Y, et al. Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-b. Immunity 2013; 38: 818-30
29. Mittag D, Proietto AI, Loudovaris T, et al. Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status. J Immunol 2011; 186: 6207-17
30. Haniffa M, Shin A, Bigley V, et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 2012; 37: 60-73
31. Klechevsky E, Morita R, Liu M, et al. Functional specializations of human epidermal Langerhans cells and CD14+dermal dendritic cells. Immunity 2008; 29: 497-510
32. Van der Aar AM, Sylva-Steenland RM, Bos JD, et al. Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol 2007; 178(4): 1986-90
33. Saito H, Frleta D, Dubsky P, Palucka AK. Dendritic Cell-Based Vaccination Against Cancer. Hematol Oncol Clin N Am 2006; 20: 689-710
34. Aspord C, Pedroza-Gonzalez A, Gallegos M, et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 2007; 204(5): 1037-47
35. De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-Associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208(3): 469-78
36. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12(4): 253-68
37. Ravichandran KS. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity 2011; 35(4): 445-55
38. Bracci L, Imerio C, Federica M, et al. Exploiting dendritic cells in the development of cancer vaccines. Expert Rev Vaccines 2013; 12(10): 1195-210
39. Samar H, Azita H, Ryan W. Hung, Afsaneh L. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Del Rev 2011; 63: 943-55
40. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N. Mature dendritic cells boost functionally superior T cells in humans without foreign helper epitopes. J Clin Invest 2000; 105: R9-R14
41. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811
42. Turley SJ, Inaba K, Garrett WS, et al. Transport of peptide-MHC class II complexes in developing dendritic cells. Science 2000; 288: 522-7
43. Inaba K, Turley S, Iyoda T, et al. The formation of immunogenic MHC class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 2000; 191: 927-36
44. Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol 2001; 22: 141-8
45. Cavallo F, Offringa R, van der Burg SH, et al. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006; 90: 175-213
46. Bonaccorsi I, Gaetana P, Barbara M, Guido F. Novel perspectives on dendritic cell-based immunotherapy of cancer. Immunol Letters 2013; 155: 6-10
47. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010; 33: 29
48. de Vries IJ, Lesterhuis WJ, Barentsz Jo, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005; 23: 1407-13
49. ÓNeill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004; 104: 2235-46
50. Chiang CL, Kandalaft LE, Tanyi J, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 2013; 19: 4801-15
51. Unger WW, van Beelen AJ, Bruijns SC, et al. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. J. Control Rel 2012; 160: 88-95
52. Weifeng Z, Lianyan W, Yuan L, et al. Immune responses to vaccines involving a combined antigene nanoparticle mixture and nanoparticle-encapsulated antigen formulation Biomaterials. 2014; 35: 6086-6097
53. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999; 11(3): 263-70
54. Lucas S, Coulie PG. About human tumor antigens to be used in immunotherapy. Semin Immunol 2008; 20: 301-7
55. Mou Z, He Y, Wu Y. Immunoproteomics to identify tumor-Associated antigens eliciting humoral response. Cancer Lett 2009; 278: 123-9
56. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-Testis antigen NYESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265-70
57. Canelle L, Bousquet J, Pionneau C, et al. An efficient proteomics-based approach for the screening of autoantibodies. J Immunol Meth 2005; 299: 77-89
58. Seliger B, Kellner R. Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets. Proteomics 2002; 2: 1641-51
59. Omenn GS. Strategies for plasma proteomics profiling of cancer. Proteomics 2006; 6: 5662-73
60. Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001; 1: 890-8
61. Lichtenfels RL, Kellner R, Atkins D, et al. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analysis. Biochim Biophys Acta 2003; 1646: 21-31
62. Gires O, Münz M, Schaffrik M, et al. Profile identification of disease-Associated humoral antigens using AMID, a novel proteomics-based technology, Cell Mol. Life Sci 2004; 64: 1198-207
63. Madrid FF. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett 2005; 230: 187-98
64. Naour FL, Brichory F, Beretta L, Hanash SM. Identification of tumor-Associated antigens using proteomics. Technol Cancer Res Treat 2002; 1: 257-62
65. Caron MG, Choquet-Kastylevsky G, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 2007; 6: 1115-22
66. Wang HL, Xu H, Lu WH, et al. In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer. Arch Gynecol Obstet 2014; 289(1): 155-62
67. Fong L Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001; 166: 4254-9
68. Ferlazzo G, Tsang ML, Moretta L, et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195: 343-51
69. Garnett MC, Kallinteri P. Nanomedicines and nanotoxicology: some physiological Principles.Occup Med(Lond). 2006; 56: 307-11
70. Joshia MD, Unger WJ, Storm G, et al. Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release 2012; 161: 25-37
71. Reddy ST, Van der Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007; 25: 1159-64
72. Moon JJ, Suh H, Li AV, et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand T-fh cells and promote germinal center induction. Proc Natl Acad Sci USA 2012; 109: 1080-108
73. Paulis LE, Mandal S, Kreutz M, Figdo CG. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr Opin Immunol 2013; 25: 389-95
74. Rettig L, Haen SP, Bittermann AG, et al. Particle size and activation threshold: a new dimension of danger signalling. Blood 2010; 115: 4533-41
75. Shortman K, Lahoud MH, Caminschi I. Improving vaccines by targeting antigens to dendritic cells. ExpMol Med 2009; 41(2): 61-6
76. Yong TL, Min B, Young WN. Enhanced cancer immunotherapy using nanoparticle-based modulation of SOCS1 genes in dendritic cells (P4242). J Immunol 2013; 190: 47.9
77. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011; 30: 16-34
78. Raghuwanshi D, Vivek M, Mavanur R, et al. A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. Vaccine 2012; 30: 7292-9
79. Hafner AM, Corthesy B, Merkle HP. Particulate formulations for the delivery of poly (I: C) as vaccine adjuvant. Adv Drug Deliv Rev 2013; 65(10): 1386-99
80. Granucci F, Foti M, Ricciardi-Castagnoli P. Dendritic cell biology. Adv Immunol 2005; 88: 193-233
81. Sehgal K, Ragheb R, Fahmy TM, et al. Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk. J Immunol 2014; 193(5): 2297-305
82. Raghuwanshi D, Mishra V, Das D, et al. Dendritic Cell Targeted Chitosan Nanoparticles for Nasal DNA Immunization against SARS CoV Nucleocapsid Protein. Mol Pharmaceutics 2012; 9(4): 946-56
83. Schliehe C, Schliehe C, Thiry M, et al. Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy. J Control Release 2011; 151: 278-28
84. Tromsdorf UI, Bigall NC, Kaul MG, et al. Size and surface effects on the MRI relaxivity of manganese ferrite nanoparticle contrast agents. Nano Lett 2007; 7: 2422-7
85. Silva JM, Mafalda V, Rogério G, et al. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 2013; 168: 179-19
86. Apostolopoulos V, Theresia T, Andreas G, et al. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv 2013; 2013: 869718
87. Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006; 12(3): 869-77
88. Tang CK, Sheng KC, Pouniotis D, et al. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-Tumorresponses.Vaccine. 2008; 26(31): 3827-34
89. Lepenies B, Junghoon L, Sonkaria S. Targeting C-Type lectin receptors with multivalent carbohydrate ligands. Adv Drug Deliv Rev 2013; 65: 1271-81
90. Singh SK, Ouwehand IS, Litjens M, et al. Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization. Eur J Immunol 2011; 41: 916-25
91. Katsara M, Matsoukas J, Deraos G, Apostolopoulos V. Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochim Biophys Sin (Shanghai) 2008; 40(7): 636-42
92. Katsara M, Yuriev E, Ramsland PA, et al. Altered peptide ligands of myelin basic protein (MBP87-99) conjugated to reduced mannan modulate immune responses in mice. Immunology 2009; 128(4): 521-33
93. Tselios TV, Lamari FN, Karathanasopoulou I, et al. Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker. Anal Biochem 2005; 347(1): 121-8
94. Sheng KC, Kalkanidis M, Pouniotis DS, et al. The adjuvanticity of a mannosylated antigen reveals TLR4 functionality essential for subset specialization and functional maturation of mouse dendritic cells. J Immunol 2008; 181(4): 2455-64
95. Cui Z, Hsu CH, Mumper RJ. Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev Ind Pharm 2003; 29(6): 689-700
96. Foged C, Arigita C, Sundblad A, et al. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004; 22(15-16): 1903-13
97. Ghotbi Z, Haddadi A, Hamdy S, et al. Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles. J Drug Target 2011; 19(4): 281-92
98. Geijtenbeek TB, Krooshoop DJ, Bleijs DA, et al. DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat Immunol 2000; 1: 353-7
99. VanKooyk Y, Unger WW, Fehres CM, et al. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol Immunol 2013; 55: 143-5
100. Mangold SL, Prost LR, Kiessling LL. Quinoxalinone inhibitors of the lectin DC-SIGN. Chem Sci 2012; 3: 772-7
101. Prost LR, Grim JC, Tonelli M, Kiessling LL. Noncarbohydrateglycomimetics and glycoprotein surrogates as DC-SIGN antagonists and agonists. ACS Chem Biol 2012; 7: 1603-8
102. Aarnoudse CA, Bax M, Sanchez-Hernandez M, et al. Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells. Int J Cancer 2008; 122: 839-46
103. Martinez-Avila O, Hijazi K, Marradi M, et al. Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN. Chem Eur J 2009; 15: 9874-88
104. Arnaiz B, Martinez-Avila O, Falcon-Perez JM, Penades S. Cellular uptake of gold nanoparticles bearing HIV gp120 oligomannosides. Bioconjug Chem 2012; 23: 814-25
105. Tabarani G, Reina JJ, Ebel C, et al. Mannose hyperbranched dendritic polymers interact with clustered organization of DC-SIGN and inhibit gp120 binding. FEBS Lett 2006; 580: 2402-8
106. Wang SK, Liang PH, Astronomo RD, et al. Targeting the carbohydrates on HIV-1: interaction of oligomannosedendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci USA 2008; 105: 3690-5
107. Garcia-Vallejo JJ, Ambrosini M. OverbeekA, et al. Multivalent glycopeptidedendrimers for the targeted delivery of antigens to dendritic cells. Mol Immunol 2012; 53: 387-97
108. Wang J, Zhang Y, Weietal J. LewisXoligosaccharidestargeting to DC-SIGN enhanced antigen-specific immune response. Immunology 2007; 121(2): 174-82
109. Unger WWJ, van Beelen AJ, Bruijns SC, et al. Glycanmodified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. J Control Release 2012; 160(1): 88-95
110. Ribeiro-Viana R, Garcia-Vallejo JJ, Collado D, et al. BODIPY-labeled DC-SIGN-Targeting glycodendrons efficiently internalize and route to lysosomes in human dendritic cells. Biomacromolecules 2012; 13: 3209-19
111. Luczkowiak J, Munoz A, Sanchez-Navarro M, et al. Glycofullerenes inhibit viral infection. Biomacromolecules 2013; 14: 431-7
112. Joshi MD, Unger WW, van Beelen AJ, et al. DC-SIGN mediated antigen-Targeting using glycanmodified liposomes: formulation considerations. Int J Pharm 2011; 416: 426-32
113. Schaefer M, Reiling N, Fessler C, et al. Decreased pathology and prolonged survival of human DC-SIGN transgenic mice during mycobacterial infection. J Immunol 2008; 180: 6836-45
114. Timpano G, Tabarani G, Anderluh M, et al. Synthesis of novel DC-SIGN ligands with an alpha-fucosylamide anchor. ChemBioChem 2008; 9: 1921-30
115. Andreini M, Doknic D, Sutkeviciute I, et al. Second generation of fucose-based DC-SIGN ligands: affinity improvement and specificity versus Langerin. Org Biomol Chem 2011; 9: 5778-86
116. Gupta RK, Siber GR. Adjuvants for humans vaccines-current status, problems and future prospects. Vaccine 1995; 13: 1263-76
117. Sallusto F, Lanzavecchia A. Heterogeneity of CD4 memory T cells: functional modules for tailored immunity. Eur J Immunol 2009; 39: 2076-82
118. Mary Disis L. Immune regulation of cancer. J Clin Oncol 2010; 28(29): 4531-8
119. Edel A, Neela M, Kingston Mills HG. Manipulating the immune system: humoral versus cell-mediated immunity. Adv Drug Deliv Rev 2001; 51: 43-54
120. Nijkamp FP, Parnham MJ. Principles of Immunopharmacology. 2011; 31: 728
121. Yang D, Zhao Y, Guo H, et al. Nanoparticles, [Gd@C82(OH)22]n, induces dendritic cell maturation and activates Th1 immune responses. ACS Nano 2010; 4(2): 1178-86
122. Reddy ST, Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007; 25: 1159-64
123. Broos S, Lundberg K, Akagi T, et al. Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: implications for specific immunotherapy. Vaccine 2010; 28: 5075-85
124. Koido S, Homma S, Hara E, et al. In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. J Translat Med 2008; 6(1): 51-7
125. Koido S, Hara E, Homma S, et al. Cancer vaccine by fusions of dendritic and cancer cells. Clin Dev Immunol 2009; 2009: 657369
126. Inaba K, Pack M, Inaba M, et al. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Experimen Med 1997; 186(5): 665-72
127. Koido S, Ohana M, Liu C, et al. Dendritic cells fused with human cancer cells: morphology, antigen expression and T cell stimulation. Clini Immunol 2004; 113(3): 261-9
128. Koido S, Hara E, Homma S, et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancerspecific antigens and induce antitumor immunity against autologous tumor cells. Clini Cancer Res 2005; 11(21): 7891-900
129. Koido S, Hara E, Homma S, et al. Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat stressed tumor cells. J Immunol 2007; 179(1): 4874-83
130. Krause SW, Neumann C, Soruri A, et al. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 2002; 25(5): 421-8
131. Haenssle HA, Krause SW, Emmert S, et al. Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study. J Immunother 2004; 27(2): 147-55
132. Kundu SK, Engleman E, Benike C, et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998; 14: 551-60
133. Lion E, Smits EL, Berneman ZN, Van Tendeloo VF. NK cells: key to success of DC-based cancer vaccines? Oncologist 2012; 17: 1256-70
134. Boudreau JE, Bridle BW, Stephenson KB, et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther 2009; 17: 1465-72
135. Hilkens CM, Isaacs JD. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now. Clin Exp Immunol 2013; 172: 148-57
136. Giannoukakis N, Phillips B, Finegold D, et al. Phase I. (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34: 2026-32
137. Thomas R, Street S, Ramnoruth N. Safety and preliminary evidence of efficacy in a phase I clinical trial of autologous tolerizing dendritic cells exposed to citrullinated peptides (Rheumavax) in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 169
138. Raich-Regue D, Grau-Lopez L, Naranjo-Gomez M, et al. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol 2012; 42: 771-82
139. Boks MA, Kager-Groenland JR, Haasjes MS, et al. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction-A comparative study of human clinical-Applicable DC. Clin Immunol 2012; 142: 332-42
140. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371-80
141. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32
142. Höltl L, Rieser C, Papesh C, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999; 161(3): 777-82
143. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61: 842-7
144. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 1999; 93: 2411-19
145. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517-26
146. Thurner B, Haendle I, Röder C, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-78
147. Mackensen A, Herbst B, Chen JL, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitrofrom CD34+hematopoietic progenitor cells. Int J Cancer 2000; 86: 385-92
148. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451-8
149. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001; 98: 8809-14
150. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61: 8513-19
151. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195: 1279-88
152. Nair SK, Morse M, Boczkowski D, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-Transfected dendritic cells. Ann Surg 2002; 235: 540-9
153. Palucka AK, Ueno H, Connolly J, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+T-cell immunity. J Immunother 2006; 29: 545-57
154. Durán-Aniotz C, Segal G, Salazar L, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 2006; 55: 819-29
155. Chang DH, Osman K, Connolly J, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of a-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005; 201: 1503-17
156. Aarntzen EH, Srinivas M, De Wilt JH, et al. Early identification of antigen-specific immune responses in vivoby [18F]-labeled 3-fluoro-3-deoxy-Thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci USA 2011; 108: 18396-9
157. Lesterhuis WJ, de Vries IJ, Schreibelt G, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011; 17: 5725-35
158. Romano E, Rossi M, Ratzinger G, et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res 2011; 17: 1984-97
159. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-Associated antigen peptides and clinical activity by vaccinations with a-Type 1polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29: 330-6
160. Fu J, Malm IJ, Kadayakkara DK, et al. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 2014; 74: 15-4042-52
161. Draube A, Klein-González N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-Analysis. PLoS One 2011; 6: e18801
162. Amos SM, Duong CP, Westwood JA, et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118: 499-509
163. Leonhartsberger N, Ramoner R, Falkensammer C, et al. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma. Cancer Immunol Immunother 2012; 6: 1407-13
164. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010; 15: 969-75
165. Aarntzen EH, De Vries IJ, Lesterhuis WJ, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73: 19-29
166. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
167. Kirkwood JM, Butterfi eld LH, Tarhini AA, et al. Immunotherapy of cancer. CA Cancer J Clin 2012; 62: 309-35
168. Motta S, Pappalardo F. Mathematical modeling of biological systems. Brief Bioinform 2012; 14(4): 411-22
169. Pappalardo F, Pennisi M, Ricupito A, et al. Induction of T cell memory by a dendritic cell vaccine: a computational model. Bioinform 2014; 30(13): 1884-91
170. Raïch-Regué D, Glancya M, Thomson AW. Regulatory dendritic cell therapy: from rodents to clinical application. Immunol Lett 2014; 161(2): 216-21